Richard Whitley to Glioma
This is a "connection" page, showing publications Richard Whitley has written about Glioma.
Connection Strength
1.569
-
Oncolytic HSV-1 for the treatment of brain tumours. Herpes. 2006 Nov; 13(3):66-71.
Score: 0.243
-
Genetically engineered human herpes simplex virus in the treatment of brain tumours. Herpes. 2001 Mar; 8(1):17-22.
Score: 0.164
-
Genetically engineered HSV in the treatment of glioma: a review. Rev Med Virol. 2000 Jan-Feb; 10(1):17-30.
Score: 0.151
-
Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther. 1998 Jan; 5(1):121-30.
Score: 0.132
-
Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res. 1997 Apr 15; 57(8):1502-9.
Score: 0.125
-
The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc Natl Acad Sci U S A. 1996 Oct 15; 93(21):11313-8.
Score: 0.121
-
Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc Natl Acad Sci U S A. 1995 Feb 28; 92(5):1411-5.
Score: 0.108
-
Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates. Hum Gene Ther Clin Dev. 2014 Mar; 25(1):16-27.
Score: 0.101
-
A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Mol Ther. 2014 May; 22(5):1048-55.
Score: 0.101
-
Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12. J Virol. 2012 May; 86(9):5304-13.
Score: 0.088
-
Serial passage through human glioma xenografts selects for a Deltagamma134.5 herpes simplex virus type 1 mutant that exhibits decreased neurotoxicity and prolongs survival of mice with experimental brain tumors. J Virol. 2006 Aug; 80(15):7308-15.
Score: 0.060
-
Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model. Neuro Oncol. 2005 Jul; 7(3):213-24.
Score: 0.055
-
Herpes simplex viruses: is a vaccine tenable? J Clin Invest. 2002 Jul; 110(2):145-51.
Score: 0.045
-
Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci U S A. 2000 Feb 29; 97(5):2208-13.
Score: 0.038
-
Ionizing radiation improves survival in mice bearing intracranial high-grade gliomas injected with genetically modified herpes simplex virus. Clin Cancer Res. 1999 Jun; 5(6):1517-22.
Score: 0.036